These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24184906)

  • 1. Complicated pathophysiology behind rituximab-induced persistent hypogammaglobulinemia.
    Kano G; Nakatani T; Yagi K; Sakamoto I; Imamura T
    Immunol Lett; 2014; 159(1-2):76-8. PubMed ID: 24184906
    [No Abstract]   [Full Text] [Related]  

  • 2. [Persistent hypogammaglobulinemia in an ITP patient following treatment with rituximab].
    Toubi E
    Harefuah; 2012 Nov; 151(11):620-1, 655. PubMed ID: 23367731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. No relapse of neuromyelitis optica during drug-induced B-lymphopenia with hypogammaglobulinemia.
    Tanaka Y; Kimura K; Kawachi I; Inuzuka T
    Neurology; 2010 Nov; 75(19):1745-7. PubMed ID: 21060099
    [No Abstract]   [Full Text] [Related]  

  • 4. Prolonged hypogammaglobulinemia after adjuvant rituximab for Hodgkin's lymphoma presenting with refractory urticaria.
    Wolverton W; McClenathan B
    Ann Allergy Asthma Immunol; 2012 Dec; 109(6):473-4. PubMed ID: 23176893
    [No Abstract]   [Full Text] [Related]  

  • 5. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy.
    Palacios T; Bartelt L; Scheld W; Lopes MB; Kelting SM; Holland S; Lipkin WI; Quan PL; Borish L; Lawrence M
    Ann Allergy Asthma Immunol; 2015 Aug; 115(2):148-50. PubMed ID: 26048250
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
    Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
    Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profound symptomatic hypogammaglobulinemia: a rare late complication after rituximab treatment for immune thrombocytopenia. Report of 3 cases and systematic review of the literature.
    Levy R; Mahévas M; Galicier L; Boutboul D; Moroch J; Loustau V; Guillaud C; Languille L; Fain O; Bierling P; Khellaf M; Michel M; Oksenhendler E; Godeau B
    Autoimmun Rev; 2014 Oct; 13(10):1055-63. PubMed ID: 25183241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on rituximab: an established treatment for all immune-mediated kidney diseases?
    Evans R; Salama AD
    Nephron Clin Pract; 2014; 126(3):97-109. PubMed ID: 24686110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
    Yi JS; Decroos EC; Sanders DB; Weinhold KJ; Guptill JT
    Muscle Nerve; 2013 Dec; 48(6):992-3. PubMed ID: 24006142
    [No Abstract]   [Full Text] [Related]  

  • 10. Rituximab treatment for vasculitis.
    Jayne D
    Clin J Am Soc Nephrol; 2010 Aug; 5(8):1359-62. PubMed ID: 20671223
    [No Abstract]   [Full Text] [Related]  

  • 11. Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab--for how long?
    Barmettler S; Price C
    J Allergy Clin Immunol; 2015 Nov; 136(5):1407-9. PubMed ID: 26277594
    [No Abstract]   [Full Text] [Related]  

  • 12. An antibody treats almost all refractory autoimmune diseases: fact and beyond.
    Lin LY; Hsu MH; Yang KD
    J Formos Med Assoc; 2012 Apr; 111(4):181-2. PubMed ID: 22655322
    [No Abstract]   [Full Text] [Related]  

  • 13. Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution.
    Sacco KA; Abraham RS
    Immunotherapy; 2018 Jun; 10(8):713-728. PubMed ID: 29569510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma.
    Yang SH; Lin LW; Fang YJ; Cheng AL; Kuo SH
    Ann Hematol; 2012 Feb; 91(2):291-4. PubMed ID: 21538062
    [No Abstract]   [Full Text] [Related]  

  • 15. [B-cell-depletion therapy in systemic autoinmune diseases. Recommendations for use in clinical practice].
    Ramos-Casals M; Díaz-Lagares C; Khamashta MA;
    Med Clin (Barc); 2011 Mar; 136(6):257-63. PubMed ID: 20627323
    [No Abstract]   [Full Text] [Related]  

  • 16. Rituximab-induced toxicity.
    Mumoli N; Cei M
    QJM; 2011 Mar; 104(3):265. PubMed ID: 20228132
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistent panhypogammaglobulinemia after CHOP-rituximab for HIV-related lymphoma.
    Miles SA; McGratten M
    J Clin Oncol; 2005 Jan; 23(1):247-8. PubMed ID: 15625386
    [No Abstract]   [Full Text] [Related]  

  • 18. Rituximab and its use in autoimmune bullous disorders.
    Daniel BS; Murrell DF; Joly P
    Dermatol Clin; 2011 Oct; 29(4):571-5. PubMed ID: 21925000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal malakoplakia in a patient with hypogammaglobulinemia.
    Thorlacius H; Jerkeman A; Marginean FE; Toth E
    Gastrointest Endosc; 2018 Sep; 88(3):563-565. PubMed ID: 29627491
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.
    Pellkofer HL; Krumbholz M; Berthele A; Hemmer B; Gerdes LA; Havla J; Bittner R; Canis M; Meinl E; Hohlfeld R; Kuempfel T
    Neurology; 2011 Apr; 76(15):1310-5. PubMed ID: 21482945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.